

SHARE BUYBACK PROGRAM NOVOZYMES A/S B SHARES

October 12, 2012

On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.

Under the program Novozymes will buy back B shares for an amount of up to DKK 1,000 million in the period from January 20, 2012, to December 31, 2012.

The following transactions have been made under the program:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	4,811,849		761,409,411
October 5, 2012	20,000	165.43	3,308,595
October 8, 2012	27,448	165.31	4,537,556
October 9, 2012	35,000	164.30	5,750,432
October 10, 2012	46,107	162.06	7,471,948
October 11, 2012	31,000	160.40	4,972,300
Accumulated under the program	4,971,404		787,450,242

Transactions related to Novozymes' incentive programs have resulted in a net sale by Novozymes of 10,535 B shares in the period from October 5, to October 11, 2012. The shares related to these transactions were not part of the Safe Harbour share buyback program.

With the transactions stated above, Novozymes owns a total of 12,643,766 treasury shares, corresponding to 3.9% of the share capital. The total amount of shares in the company is 325,000,000 including treasury shares.

Contact persons:

Press and media:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Investor relations:

Maarit Pokkinen

Tlf. (direkte): +45 4446 8682

Tlf. (mobil): +45 3077 8682

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.